Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joachim Havla

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
MMW Fortschritte Der Medizin|July 3, 2016
[Not Available]Joachim Havla
Deutsches Arzteblatt International|May 23, 2017
In ReplyJoachim Havla
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 15, 2022
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting RepairJoachim Havla, Reinhard Hohlfeld
Therapeutics and Clinical Risk Management|October 15, 2013
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Joachim Havla, Ingo Kleiter, Tania Kümpfel
Multiple Sclerosis and Related Disorders|April 17, 2015
Late-onset neutropenia during long-term rituximab therapy in neuromyelitis opticaAnnika Plate, Joachim Havla, Tania Kümpfel
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2017
Patient-to-patient transmission of natalizumab-associated PML?Reinhard Hohlfeld, Joachim Havla, Tania Kümpfel
Journal of Neurology|November 27, 2013
Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstemJoachim Havla, Reinhard Hohlfeld, Tania Kümpfel
MMW Fortschritte Der Medizin|April 14, 2010
[Progress of therapy in patients with multiple sclerosis]Tania Kümpfel, Joachim Havla, Reinhard Hohlfeld
Multiple Sclerosis and Related Disorders|December 29, 2024
Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosisBegüm Irmak Ön, Joachim Havla, Ulrich Mansmann
Journal of Central Nervous System Disease|June 29, 2026
Correlation Is Not Prediction: Reassessing Predictive MRI Evidence in Guidelines for Persons With Relapsing-Remitting Multiple SclerosisDulat Minas, Stefan Buchka, Joachim Havla, et al.
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
MMW Fortschritte Der Medizin|July 3, 2016
[Not Available]Joachim Havla
Deutsches Arzteblatt International|May 23, 2017
In ReplyJoachim Havla
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 15, 2022
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting RepairJoachim Havla, Reinhard Hohlfeld
Therapeutics and Clinical Risk Management|October 15, 2013
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Joachim Havla, Ingo Kleiter, Tania Kümpfel
Multiple Sclerosis and Related Disorders|April 17, 2015
Late-onset neutropenia during long-term rituximab therapy in neuromyelitis opticaAnnika Plate, Joachim Havla, Tania Kümpfel
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2017
Patient-to-patient transmission of natalizumab-associated PML?Reinhard Hohlfeld, Joachim Havla, Tania Kümpfel
Journal of Neurology|November 27, 2013
Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstemJoachim Havla, Reinhard Hohlfeld, Tania Kümpfel
MMW Fortschritte Der Medizin|April 14, 2010
[Progress of therapy in patients with multiple sclerosis]Tania Kümpfel, Joachim Havla, Reinhard Hohlfeld
Multiple Sclerosis and Related Disorders|December 29, 2024
Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosisBegüm Irmak Ön, Joachim Havla, Ulrich Mansmann
Journal of Central Nervous System Disease|June 29, 2026
Correlation Is Not Prediction: Reassessing Predictive MRI Evidence in Guidelines for Persons With Relapsing-Remitting Multiple SclerosisDulat Minas, Stefan Buchka, Joachim Havla, et al.
Pageof 13